Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Charité Establishes NanoTherm® Therapy for the Treatment of Recurrent Brain Tumors

Abstract:
Charité - Universitätsmedizin Berlin has established a new treatment at the Clinic for Radiooncology, Campus Virchow, which offers selected patients a nanomedicine approach for the treatment of recurrent brain tumors. Researchers at Charité-developed the scientific basis for the nanotechnology-based cancer therapy. The clinical trial supporting the therapy's European approval was also conducted in close collaboration with the Charité. MagForce Nanotechnologies AG, a Charité spin off company, is marketing the therapy.

Charité Establishes NanoTherm® Therapy for the Treatment of Recurrent Brain Tumors

Berlin, Germany | Posted on July 8th, 2011

The principle of the therapy is the use of nanoparticles containing iron oxide, which are injected into brain tumor in a procedure similar to a biopsy. The treatment is carried out in a magnetic field applicator (NanoActivator™), a machine that produces an alternating magnetic field and is very safe for humans. Through this high frequency magnetic field, the nanoparticles begin to oscillate and heat is produced from directly within the tumor tissue. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation. This novel therapy has the potential to improve the survival for patients with recurrent glioblastoma, an especially malignant type of brain tumor.

"I am pleased that after years of being involved in the research and development for NanoTherm® Therapy, we are now at the stage where we can offer this novel therapeutic approach to selected and not otherwise treatable patients suffering from recurrent glioblastomas," said Prof. Volker Budach, Director of the Clinic for Radiotherapy.

"Here is another example of how the basic research we are supporting today has clinical applications in the future", said Prof. Karl Max Einhäupl, CEO of Charité. "Charité has participated in all development phases of this novel medical technology and most importantly supported our researchers to realize the potential of their ideas, especially in the challenging field of nanomedicine."

Currently, the social insurance companies do not generally reimburse this new treatment option so that payment decisions are based on individual applications.

####

For more information, please click here

Contacts:
Claudia Peter
+49 (0) 30 450 570 400

Copyright © AlphaGalileo

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Announcements

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE